10-Q quarterly report · filed Nov 5, 2026

Monte Rosa Therapeutics, Inc. (GLUE) Q3 2026 10-Q Quarterly Report

Short answer

Monte Rosa Therapeutics, Inc. (GLUE) filed its Q3 2026 10-Q quarterly report on Nov 5, 2026 for the quarter ended Sep 30, 2026. Quarterly revenue was $54M (up 325.8% year over year) with net income of $3M.

Q3 2026 key financials · XBRL

Revenue
$54M
+325.8% YoY · +506.2% QoQ
Net income
$3M
+111.3% YoY · +107.1% QoQ
Operating margin
-3.6%

Source: XBRL data from the Monte Rosa Therapeutics, Inc. (GLUE) Q3 2026 10-Q on SEC EDGAR. USD.

Monte Rosa Therapeutics, Inc. Q3 2026 10-Q analysis

AI summary of MD&A and risk factor updates

Management Discussion & Analysis

  • Quarterly collaboration revenue $54.4M, up $41.6M YoY from $12.8M
  • Net income $3.1M vs $27.1M loss YoY, operating margin (3.6%) vs (72.1%)
  • MRT-8102 largest R&D line at $5.6M, MRT-6160 lowest at $1.4M
  • Cash, equivalents, restricted cash and securities $582.6M; operating cash flow $(122.5)M
  • $323.8M net proceeds from 2026 offering; cash runway expected into 2029

Risk Factors

  • Continued operating losses, net loss $84.8 million for nine months ended September 30, 2026
  • Cash, equivalents, restricted cash and marketable securities $582.6 million as of September 30, 2026
  • Development spending risk: Phase 2 trials for MRT-2359 and MRT-8102 increasing expenses
  • Profitability risk: accumulated deficit reached $562.1 million as of September 30, 2026

Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K

Other Monte Rosa Therapeutics, Inc. quarterly reports

Ask about this quarter

Compare quarters, check guidance or see what insiders and funds did around the report.